{"id":1877,"date":"2026-05-06T18:33:02","date_gmt":"2026-05-06T16:33:02","guid":{"rendered":"https:\/\/sites.unica.it\/pe2026\/?p=1877"},"modified":"2026-05-07T17:58:32","modified_gmt":"2026-05-07T15:58:32","slug":"pierfrancesco-cinque","status":"publish","type":"post","link":"https:\/\/sites.unica.it\/pe2026\/2026\/05\/06\/pierfrancesco-cinque\/","title":{"rendered":"Pierfrancesco Cinque"},"content":{"rendered":"\n
\n\n\n\n
\"\"<\/figure>
\n

FPC1 – Pierfrancesco Cinque<\/strong><\/p>\n\n\n\n

University of Naples Federico II – Department of Pharmacy<\/p>\n\n\n\n

pierfrancesco.cinque@unina.it<\/strong><\/p>\n\n\n\n

<\/p>\n<\/div><\/div>\n\n\n\n

Design and synthesis of molecular hybrids between drugs for dermatological disorders or wound healing and h2s donors<\/strong><\/td><\/tr>
Pierfrancesco Cinque1<\/sup>,<\/em><\/em> Giuseppe Caliendo1<\/sup>, Vincenzo Santagada1<\/sup>, Rosa Sparaco1<\/sup>, Vincenzo Calderone2<\/sup>, Valentina Citi2<\/sup>, Angela Ianaro1<\/sup>,Giuseppe Ercolano1<\/sup>, Barbara Maglione3<\/sup> and Francesco Frecentese1<\/sup>.
<\/em> 
1<\/sup> Department of Pharmacy, University of Naples Federico II, Via D. Montesano 49, 80131 Naples, Italy
2<\/sup> Department of Pharmacy, University of Pisa, Via Bonanno, 6 ,56126, Pisa, Italy
3<\/sup> Farmaceutici Damor Spa, Via Emilio Scaglione, <\/sup>27, 80145 Napoli, Italy<\/td><\/tr>
Abstract<\/strong>
The research project focuses on the development of molecular hybrids combining JAK kinase inhibitors, approved for dermatological diseases such as atopic dermatitis, psoriasis and vitiligo, with H\u2082S-releasing moieties able to mimic physiological hydrogen sulfide release [1]. These diseases are characterized by abnormal immune activation and chronic inflammation, with periods of clinical stability alternating with flare-ups.
In this study, molecular hybrids based on JAK-STAT pathway inhibitors, such as Abrocitinib and Peficitinib, were designed and synthesized by conjugating the JAK-inhibiting pharmacophore with selected H\u2082S donors, namely TBZ, ADT-OH and HBTA. This strategy aims to combine the anti-inflammatory activity mediated by JAK-STAT pathway inhibition with the well-known biological properties of H\u2082S [2]. TBZ is commercially available, whereas ADT-OH and HBTA were prepared according to published procedures [3,4]. Compounds I\u2013VI were evaluated for cytotoxicity in HaCaT keratinocytes at different concentrations ranging from 0.01 to 100 \u00b5M. Their H\u2082S-releasing profile was also assessed in the presence and absence of L-cysteine. In vitro pharmacological studies were performed at 5 \u00b5M, including scratch test assays to evaluate their wound healing potential. Overall, compounds I\u2013VI showed promising results, with HBTA and ADT-OH derivatives, particularly compounds II, III, V and VI, displaying the best activity and promoting complete wound closure within 48\u201372 h. Further studies are ongoing to assess their anti-inflammatory activity and to confirm JAK-STAT pathway inhibition through molecular biology assays.<\/td><\/tr>
References  <\/strong>
[1] Samadi, A.; Nasrollahi, S. A.; Hashemi, A.; Nassiri Kashani, M.; Firooz, A. Janus Kinase (JAK) Inhibitors for the Treatment of Skin and Hair Disorders: A Review of Literature. J. Dermatol. Treat.<\/em> 2017<\/strong>, 28<\/em> (6), 476\u2013483.  DOI: 10.1080\/09546634.2016.1277179<\/a>
[2] Magli, E.; Perissutti, E.; Santagada, V.; Caliendo, G.; Corvino, A.; Esposito, G.; Fiorino, F.; Migliaccio, M.; Scognamiglio, A.; Severino, B.; Sparaco, R.; Frecentese, F. H\u2082S Donors and Their Use in Medicinal Chemistry. Biomolecules<\/em> 2021<\/strong>, 11<\/em> (12), 1899. DOI: 10.3390\/biom11121899<\/a>
[3] Wallace, J. L.; Caliendo, G.; Sparatore, A.; Santagada, V.; Fiorucci, S. Derivatives of 4- or 5-Aminosalicylic Acid. Patent WO2006125293, 2006.
[4] Ercolano, G.; De Cicco, P.; Frecentese, F.; Saccone, I.; Corvino, A.; Giordano, F.; Magli, E.; Fiorino, F.; Severino, B.; Calderone, V.; Citi, V.; Cirino, G.; Ianaro, A. Anti-Metastatic Properties of Naproxen-HBTA in a Murine Model of Cutaneous Melanoma. Front. Pharmacol.<\/em> 2019<\/strong>, 10<\/em>, 66. DOI: 10.3389\/fphar.2019.00066<\/a><\/td><\/tr><\/tbody><\/table><\/div><\/figure>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

FPC1 – Pierfrancesco Cinque University of Naples Federico II – Department of Pharmacy pierfrancesco.cinque@unina.it Design and synthesis of molecular hybrids between drugs for dermatological disorders or wound healing and h2s donors Pierfrancesco Cinque1, Giuseppe Caliendo1, Vincenzo […]<\/p>\n","protected":false},"author":10371,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1877","post","type-post","status-publish","format-standard","hentry","category-senza-categoria"],"_links":{"self":[{"href":"https:\/\/sites.unica.it\/pe2026\/wp-json\/wp\/v2\/posts\/1877","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sites.unica.it\/pe2026\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sites.unica.it\/pe2026\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sites.unica.it\/pe2026\/wp-json\/wp\/v2\/users\/10371"}],"replies":[{"embeddable":true,"href":"https:\/\/sites.unica.it\/pe2026\/wp-json\/wp\/v2\/comments?post=1877"}],"version-history":[{"count":6,"href":"https:\/\/sites.unica.it\/pe2026\/wp-json\/wp\/v2\/posts\/1877\/revisions"}],"predecessor-version":[{"id":2135,"href":"https:\/\/sites.unica.it\/pe2026\/wp-json\/wp\/v2\/posts\/1877\/revisions\/2135"}],"wp:attachment":[{"href":"https:\/\/sites.unica.it\/pe2026\/wp-json\/wp\/v2\/media?parent=1877"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sites.unica.it\/pe2026\/wp-json\/wp\/v2\/categories?post=1877"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sites.unica.it\/pe2026\/wp-json\/wp\/v2\/tags?post=1877"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}